JP2023513752A5 - - Google Patents
Info
- Publication number
- JP2023513752A5 JP2023513752A5 JP2022548955A JP2022548955A JP2023513752A5 JP 2023513752 A5 JP2023513752 A5 JP 2023513752A5 JP 2022548955 A JP2022548955 A JP 2022548955A JP 2022548955 A JP2022548955 A JP 2022548955A JP 2023513752 A5 JP2023513752 A5 JP 2023513752A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cancer
- fragment
- polynucleotide according
- pathway
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200018169 | 2020-02-14 | ||
| KR10-2020-0018169 | 2020-02-14 | ||
| PCT/KR2021/001904 WO2021162521A1 (ko) | 2020-02-14 | 2021-02-15 | 외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513752A JP2023513752A (ja) | 2023-04-03 |
| JP2023513752A5 true JP2023513752A5 (enExample) | 2024-02-26 |
Family
ID=77291621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548955A Pending JP2023513752A (ja) | 2020-02-14 | 2021-02-15 | 外部から導入された細胞シグナル伝達調節因子を過剰発現する免疫細胞及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230212254A1 (enExample) |
| EP (1) | EP4105232A4 (enExample) |
| JP (1) | JP2023513752A (enExample) |
| KR (1) | KR20210103975A (enExample) |
| CN (1) | CN115427451B (enExample) |
| AU (1) | AU2021219233A1 (enExample) |
| TW (1) | TW202146440A (enExample) |
| WO (1) | WO2021162521A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
| WO2024121426A1 (en) * | 2022-12-09 | 2024-06-13 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Method for optimizing t cells for immuno-therapy |
| JP2026507228A (ja) | 2023-03-03 | 2026-02-27 | アーセナル バイオサイエンシズ インコーポレイテッド | Ｐｓｍａ及びｃａ９を標的とするシステム |
| CN116355859B (zh) * | 2023-05-31 | 2023-08-11 | 四川大学华西医院 | 包含shp2 n-sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用 |
| CN116376844B (zh) * | 2023-05-31 | 2023-08-11 | 四川大学华西医院 | 包含shp2 sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用 |
| CN116814664B (zh) * | 2023-08-25 | 2023-12-12 | 中国医学科学院肿瘤医院 | 一种扩展肿瘤识别表位的cea嵌合抗原受体t细胞的制备与应用 |
| WO2025111277A2 (en) * | 2023-11-20 | 2025-05-30 | Carisma Therapeutics Inc. | Compositions and methods relating to redirected soluble modulators |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4619651B2 (ja) | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| SI3300745T1 (sl) * | 2013-02-15 | 2020-01-31 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njihove uporabe |
| DK3597742T3 (da) * | 2014-10-09 | 2022-10-03 | Univ Yamaguchi | Car-udtrykkende vektor og car-udtrykkende t-celler |
| WO2018044866A1 (en) * | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| DK3541833T5 (da) * | 2016-11-17 | 2024-09-02 | 2Seventy Bio Inc | TGFß signalkonverter |
| GB201620070D0 (en) * | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| SG11201906552WA (en) * | 2017-01-25 | 2019-08-27 | Tessa Therapeutics Pte Ltd | TGF-ß DECOY RECEPTOR |
| CA3053640A1 (en) * | 2017-02-17 | 2018-08-23 | Unum Therapeutics Inc. | Co-use of anti-bcma antibody and antibody-coupled t celll receptor (actr) in cancer therapy and b cell disorders |
| CN110831961B (zh) * | 2017-03-03 | 2024-01-02 | 黑曜石疗法公司 | 用于免疫疗法的cd19组合物和方法 |
| CA3057306A1 (en) * | 2017-03-22 | 2018-09-27 | Novartis Ag | Biomarkers and car t cell therapies with enhanced efficacy |
| JP2020524512A (ja) * | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| CN108218999B (zh) * | 2018-01-02 | 2021-06-11 | 广东省人民医院(广东省医学科学院) | 分泌il-7的嵌合抗原受体、病毒载体、表达细胞及制备方法与药物 |
| CN109265565B (zh) * | 2018-10-10 | 2021-06-01 | 苏州大学 | 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用 |
| WO2020123947A1 (en) * | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
-
2021
- 2021-02-15 KR KR1020210019765A patent/KR20210103975A/ko active Pending
- 2021-02-15 CN CN202180028871.2A patent/CN115427451B/zh active Active
- 2021-02-15 WO PCT/KR2021/001904 patent/WO2021162521A1/ko not_active Ceased
- 2021-02-15 JP JP2022548955A patent/JP2023513752A/ja active Pending
- 2021-02-15 US US17/904,221 patent/US20230212254A1/en active Pending
- 2021-02-15 AU AU2021219233A patent/AU2021219233A1/en active Pending
- 2021-02-15 EP EP21753514.5A patent/EP4105232A4/en active Pending
- 2021-02-17 TW TW110105348A patent/TW202146440A/zh unknown